TICKERNERD
Menu
TRAXHealthcare · Biotechnology

TRAX Stock Forecast: First Tracks Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$36
−4.05% on the day

The 9 Wall Street analysts covering First Tracks Biotherapeutics, Inc. hold a median 12-month price target of $65 — +78.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 10 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
1 / 100
Median analyst target
$65
Analysts covering
9
Revenue$0.0
Operating income−$34.9M
Net income−$33.4M
Free cash flow−$31.9M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.3%
1M
−22.1%
From high
−24.0%
From low
+137.9%
$15
$48
Range since 15 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

TRAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores First Tracks Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
41
Revisions
29
Momentum
12
Value
11
Issuance
8
Growth
8
Accruals
8
Quality
4
Volatility
3

Size (41): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 15 Apr 2026Adjusted close, US dollars
$20$40$60$80$100May 26Jun 26Jul 26Aug 26Sep 26TRAXHigh $95Median $65Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $55Median $65High $95

The green dot is the last close — the median target sits +78.4% from it.

Recent analyst actionsNewest first

Of the 18 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$57
13 Aug 2026BarclaysMaintainsOverweight$48 → $65
13 Aug 2026HC Wainwright & Co.MaintainsBuy$44 → $57
13 Aug 2026Piper SandlerMaintainsOverweight$54 → $95
13 Aug 2026WedbushMaintainsOutperform$60 → $70
10 Aug 2026UBSMaintainsBuy$45 → $65
28 July 2026WedbushMaintainsOutperform$30 → $60
28 July 2026Wells FargoMaintainsOverweight$30 → $55
21 July 2026BarclaysMaintainsOverweight$40 → $48
10 July 2026HC Wainwright & Co.MaintainsBuy$30 → $44
8 July 2026HC Wainwright & Co.ReiteratesBuy$30
8 June 2026Wells FargoInitiatesOverweight$30
4 May 2026Piper SandlerInitiatesOverweight$54
28 Apr 2026HC Wainwright & Co.InitiatesBuy$30
24 Apr 2026Leerink PartnersInitiatesOutperform$46
23 Apr 2026JP MorganInitiatesOverweight$31
22 Apr 2026BarclaysInitiatesOverweight$40
21 Apr 2026UBSInitiatesBuy$45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TRAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

TRAX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200May 26Jun 26Jul 26Aug 26Sep 26TRAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

First Tracks Biotherapeutics, Inc. (TRAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
8.0×

Cheaper than 12% of US stocks

EV / EBITDA
−7.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−41.8%

Higher than 24% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

First Tracks Biotherapeutics, Inc. (TRAX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • First Tracks Biotherapeutics, Inc. has a market value of $1.4B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$173.5M.

  • Diluted earnings per share, trailing twelve months: $−4.98.

  • Free cash flow in the twelve months to 30 June 2026: −$148.2M.

  • Shares outstanding: 35.4M.

  • forward P/E: −10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • First Tracks Biotherapeutics, Inc. employs 104 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

TRAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRAXFirst Tracks Biotherapeutics, Inc.$1.4B
1
OMEROmeros Corp.$1.3B
93
VORVor Biopharma, Inc.$1.3B
15
AKTSAktis Oncology, Inc.$1.3B
2
IMTXImmatics NV$1.3B
40
CGEMCullinan Therapeutics, Inc.$1.3B
69
LTGOLatigo Biotherapeutics, Inc.$1.4B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own First Tracks Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRAX news & analysis

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

GlobeNewsWire · 26 Aug 2026neutral

First Tracks Biotherapeutics, a clinical-stage biotechnology company advancing antibody therapeutics for autoimmune and inflammatory diseases, announced that members of its executive team are scheduled to participate in multiple investor conferences in September. This was disclosed in an Aug. 26, 2026 press release from San Diego.

Why it matters — The company's executive team's participation in upcoming investor conferences provides an opportunity for increased visibility and engagement with the investment community.

FAQ

Frequently asked questions about TRAX stock

What is the TRAX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering First Tracks Biotherapeutics, Inc. have a median 12-month price target of $65, with estimates ranging from $55 to $95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRAX stock a buy right now?

Of the 9 analysts covering First Tracks Biotherapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks First Tracks Biotherapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRAX?

As at 10 Sept 2026, First Tracks Biotherapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (41 of 100).

Will TRAX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +78.4% from the last close, and Ticker Nerd's factor model ranks First Tracks Biotherapeutics, Inc. 1 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRAX stock forecast for 2030?

No analyst covering First Tracks Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $95 over the next 12 months.

What does First Tracks Biotherapeutics, Inc. do?

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases.

What is the latest news on TRAX?

The most recent item we track (GlobeNewsWire, 26 Aug 2026): "First Tracks Biotherapeutics Announces Participation in September Investor Conferences". First Tracks Biotherapeutics, a clinical-stage biotechnology company advancing antibody therapeutics for autoimmune and inflammatory diseases, announced that members of its executive team are scheduled to participate in multiple investor conferences in September. This was disclosed in an Aug. 26, 2026 press release from San Diego.

Company

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases. First Tracks Biotherapeutics develops immunology programs designed to modulate key immune pathways and address diseases driven by dysregulated immune responses. Its current pipeline centers on rosnilimab, ANB033, and ANB101, which are being studied as targeted antibody therapies across indications such as rheumatoid arthritis, celiac disease, and eosinophilic esophagitis. The company’s work is concentrated on research and development, with an emphasis on precision approaches that interact with immune-cell signaling and pathogenic T-cell activity. Based in San Diego, California, First Tracks Biotherapeutics plays a specialized role in the biotechnology market by advancing next-generation therapies for immune-mediated conditions.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.firsttracksbio.com